[Cyclic GMP as a biomarker for cardiovascular disease and cancer].
BACKGROUND
Levels of cyclic guanosine 3',5'-monophosphate (cGMP) are elevated in plasma and urine from patients with some cardiovascular diseases and some types of cancer.


METHODS
This paper is based on studies of cGMP as a biomarker.


CONCLUSIONS
It is well documented that cGMP levels are elevated in plasma in patients with heart failure and various leukaemias and in urine from patients with gynaecological cancers. Because of great interindividual variation in levels, cGMP is less suitable in primary diagnostics, but appears to be a sensitive marker in individual follow up in some diseases.
Ulvestad
Line
L
Klinisk farmakologisk avdeling, Universitetssykehuset Nord-Norge, 9038 Tromsø.
Sager
Georg
G
D015415:Biomarkers / Q000032:analysis* / Q000097:blood / Q000652:urine; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood / Q000652:urine; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000201:enzymology*; D006152:Cyclic GMP / Q000032:analysis* / Q000097:blood / Q000652:urine; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000201:enzymology; D006801:Humans; D007938:Leukemia / Q000175:diagnosis / Q000201:enzymology; D008297:Male; D009369:Neoplasms / Q000175:diagnosis / Q000201:enzymology*
D015415:Biomarkers; D014408:Biomarkers, Tumor; D006152:Cyclic GMP